Zentalis Pharmaceuticals Inc (ZNTL) Implied Volatility Current

Tracking ZNTL implied volatility helps you identify when options premiums on Zentalis Pharmaceuticals Inc are historically cheap or expensive, and where the best trades are hiding. Zentalis Pharmaceuticals Inc implied volatility reflects the market's expectation of future price movement: when ZNTL IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Zentalis Pharmaceuticals Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For ZNTL, tracking metrics like ZNTL IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on ZNTL signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.

The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where ZNTL implied volatility sits today versus where it has been. Our scanner ranks Zentalis Pharmaceuticals Inc implied volatility against its historical range, surfaces extremes in ZNTL IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Zentalis Pharmaceuticals Inc IV is rich or cheap — measure it, then act on it.